CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.79 USD
+0.05 (0.11%)
Updated Sep 24, 2024 04:00 PM ET
Pre-Market: $46.81 +0.02 (0.04%) 8:28 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Earnings News For CRSP
-
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
-
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
-
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
-
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
-
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
-
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
-
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
-
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
-
CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
-
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
-
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
-
CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know
-
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
-
CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
-
CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected
-
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results